Showing 15 of 55 recruiting trials for “classic-hodgkin-lymphoma”
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
👨⚕️ Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC📍 31 sites📅 Started Aug 2022View details ↗
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
👨⚕️ Wenbin Qian, 2nd Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Jul 2022View details ↗
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
👨⚕️ Kristie Blum, MD, Emory University Hospital/Winship Cancer Institute📍 2 sites📅 Started May 2022View details ↗
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
👨⚕️ Christopher J Melani, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Feb 2018View details ↗
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →